


Financial highlights

Revenue £'000

£95,780




EBITDA £'000

£1,318




Net debt £'000

£0




Cash balance £'000

£101,746



Gross margin £'000

£29,678*



* After cost of sales exceptional items

Operational highlights

- Rapid development and launch of 15 new assays to support laboratories, clinicians, and private testing of COVID-19 since the beginning of 2021
- Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing
- Inclusion in National Framework Agreement, resulting in a new £4.7 million contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS
- Secured new contracts with a leading global health organisation and UNICEF for the supply of COVID-19 products
- Growth of new markets for private testing, including travel, sport, film, media, and workplace settings

Business Overview

Novacyt's Key Strengths	02
Group at a Glance	04
Customer Testimonials	08

Strategic Report

Chairman's Statement	12
Development and Manufacturing Capability	14
Our Strategy	16
Market Spotlight	18
Shaping the future with the right portfolio	20
Q&A with CEO	22
Chief Executive Officer's report	24
Section 172(1) Statement	26
Financial Review	27
Sustainability	31

Governance

The Board of Directors	40
Directors' report	43
An introduction from the Chairman	46
QCA principles	48
Nomination Committee report	56
Directors' Remuneration report	57
Audit Committee report	61
Principal Risks and Risk Management	64

Financial Statements

Statement of Directors' responsibilities in respect of the annual report and financial statements	72
Statutory auditor's report on the consolidated financial statements	74
Accounts and notes	
Consolidated income statement	76
Consolidated statement of comprehensive income	77
Statement of financial position	78
Statement of changes in equity	79
Statement of cash flows	80
Notes to the annual accounts	81

Glossary of terms

Glossary of terms	128
Company Information	129